Опухоли головы и шеи. 2022; 12: 72-78
Оценка распространенности ВПЧ-положительного плоскоклеточного рака ротоглотки на примере отдельной выборки в Российской Федерации
https://doi.org/10.17650/2222-1468-2022-12-1-72-78Аннотация
Введение. Прирост заболеваемости плоскоклеточным раком ротоглотки во всем мире в последние десятилетия дал старт множеству исследований в данной области. Благодаря этому в 2005 г. был обозначен новый этиологический фактор в развитии этого вида опухолей – вирус папилломы человека. На сегодняшний день известно, что ассоциированный с данным вирусом плоскоклеточный рак ротоглотки является заболеванием с уникальными характеристиками. Исследование эпидемиологии этой патологии на российской популяции пациентов представляется актуальной научной задачей.
Цель исследования – изучение частоты и распространенности плоскоклеточного рака ротоглотки, ассоциированного с вирусом папилломы человека, в России на примере определенной выборки пациентов.
Материалы и методы. Был проведен анализ данных 199 пациентов с плоскоклеточным раком ротоглотки, получавших лечение в Национальном медицинском исследовательском центре онкологии им. Н. Н. Б лохина Минздрава России с 2016 по 2021 г. Исследовались частота ассоциации опухоли с вирусом папилломы человека, возраст, пол, распространенность и стадия опухолевого процесса в зависимости от р16‑статуса.
Результаты. В исследованной когорте пациентов в 58,3 % случаев выявлена ассоциация опухоли с вирусом папилломы человека. Пик заболеваемости приходится на возраст от 45 до 64 лет (более 60 % случаев). У мужчин заболевание встречается в 2 раза чаще, чем у женщин. У 60,9 % пациентов с р16‑положительными опухолями наблюдается I стадия процесса, а у 51,2 % пациентов с р16‑отрицательными новообразованиями – IV стадия.
Заключение. Полученные на отдельной выборке российских пациентов данные сопоставимы с данными мировой литературы.
Список литературы
1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660.
2. Gillison M.L., Koch W.M., Capone R.B. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92(9):709–20. DOI: 10.1093/jnci/92.9.709.
3. Arbyn M., Bosch X., Cuzick J. et al. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 90. Human papillomaviruses. Lyon: World Health Organization, 2007. 670 p. Avaliable at: https://monographs.iarc.who.int/wpcontent/uploads/2018/06/mono90.pdf.
4. Ang K.K., Harris J., Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24–35. DOI: 10.1056/NEJMoa0912217.
5. Cancer incidence in five continents. Ed. by D.M. Parkin, S.L. Whelan, J. Ferlay et al. IARC CancerBase Vol. 1–8. No. 7. Lyon, France: International Agency for Research on Cancer, 2005.
6. Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.
7. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. J Clin 2018;68(6): 394–424. DOI: 10.3322/caac.21492.
8. Fakhry C., Westra W.H., Wang S.J. et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer 2017;123(9):1566–75. DOI: 10.1002/cncr.30353.
9. De Martel C., Georges D., Bray F. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8(2):e180–190. DOI: 10.1016/S2214109X(19)304887.
10. O’Rorke M.A., Ellison M.V., Murray L.J. et al. Human papillomavirus related head and neck cancer survival: a systematic review and metaanalysis. Oral Oncol 2012;48(12):1191–201. DOI: 10.1016/j.oraloncology.2012.06.019.
11. Mahal B.A., Catalano P.J., Haddad R.I. et al. Incidence and demographic burden of HPVassociated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol Biomarkers Prev 2019;28(10):1660–7. DOI: 10.1158/10559965.EPI190038.
12. Chaturvedi A.K., Engels E.A., Pfeiffer R.M. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol 2011;29(32):4294–301. DOI: 10.1200/JCO.2011.36.4596.
13. Stjernstrøm K.D., Jensen J.S., Jakobsen K.K. et al. Current status of human papillomavirus positivity in oropharyngeal squamous cell carcinoma in Europe: a systematic review. Acta Otolaryngol 2019; 139(12):1112–6. DOI:10.1080/00016489.2019.1669820.
14. Mooren J.J., Gültekin S.E., Straetmans J.M. et al. P16 (INK4A) immunostaining is a strong indicator for highriskHPVassociated oropharyngeal carcinomas and dysplasias, but is unreliable to predict lowriskHPVinfection in head and neck papillomas and laryngeal dysplasias. Int J Cancer 2014;134(9):2108–17. DOI: 10.1002/ijc.28534.
15. Visalli G., Riso R., Facciolà A. et al. Higher levels of oxidative DNA damage in cervical cells are correlated with the grade of dysplasia and HPV infection. J Med Virol 2016;88(2):336–44. DOI: 10.1002/jmv.24327.
16. Prigge E.S., Arbyn M., von Knebel Doeberitz M., Reuschenbach M. Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and metaanalysis. Int J Cancer 2017;140(5): 1186–98. DOI: 10.1002/ijc.30516.
17. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129.
18. Human papillomavirus testing in head and neck carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline J Clin Oncol 2018;36(31):3152–61. DOI: 10.1200/JCO.18.00684.
19. Мудунов А.М. Вирус папилломы человека – новый этиологический фактор в развитии рака органов головы и шеи. Проблемы и перспективы их решения. Эпидемиология и вакцинопрофилактика 2018; 17(5):100–5. DOI: 10.31631/207330462018175100105.
Head and Neck Tumors (HNT). 2022; 12: 72-78
Estimation of the prevalence of HPV-positive squamous cell carcinoma of the oropharynx on the example of a separate sample in the Russian Federation
https://doi.org/10.17650/2222-1468-2022-12-1-72-78Abstract
Introduction. The increasing incidence of oropharyngeal squamous cell carcinoma observed globally in recent decades gave rise to research in this area. In 2005, human papillomavirus was proved to be an etiological factor of oropharyngeal squamous cell carcinoma. Currently, oropharyngeal squamous cell carcinoma associated with human papillomavirus is believed to have some unique characteristics. The analysis of oropharyngeal squamous cell carcinoma epidemiology appears to be highly relevant.
Objective – to assess the incidence and prevalence of oropharyngeal squamous cell carcinoma associated with human papillomavirus in Russia on the example of a certain sample of patients.
Materials and methods. We analyzed medical records of 199 oropharyngeal squamous cell carcinoma patients treated in N. N. Blokhin Russian Cancer Research Center between 2016 and 2021. We analyzed the frequency of tumors associated with human papillomavirus, age, sex, tumor spread and stage depending on р16 status.
Results. More than half of the patients from our cohort (58.3 %) were р16‑positive. The peak incidence was observed in individuals aged 45 to 64 years (more than 60 % of cases). Males were twice as likely to have р16‑positive tumors than females. A total of 60.9 % of patients with р16‑positive tumors had stage I disease, whereas 51.2 % of patients with p16‑negative tumors had stage IV disease.
Conclusion. The results obtained for a sample of Russian patients are comparable with the findings of foreign authors.
References
1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660.
2. Gillison M.L., Koch W.M., Capone R.B. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92(9):709–20. DOI: 10.1093/jnci/92.9.709.
3. Arbyn M., Bosch X., Cuzick J. et al. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 90. Human papillomaviruses. Lyon: World Health Organization, 2007. 670 p. Avaliable at: https://monographs.iarc.who.int/wpcontent/uploads/2018/06/mono90.pdf.
4. Ang K.K., Harris J., Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24–35. DOI: 10.1056/NEJMoa0912217.
5. Cancer incidence in five continents. Ed. by D.M. Parkin, S.L. Whelan, J. Ferlay et al. IARC CancerBase Vol. 1–8. No. 7. Lyon, France: International Agency for Research on Cancer, 2005.
6. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2019 godu. Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shakhzadovoi. M.: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2020. 239 s.
7. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. J Clin 2018;68(6): 394–424. DOI: 10.3322/caac.21492.
8. Fakhry C., Westra W.H., Wang S.J. et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer 2017;123(9):1566–75. DOI: 10.1002/cncr.30353.
9. De Martel C., Georges D., Bray F. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8(2):e180–190. DOI: 10.1016/S2214109X(19)304887.
10. O’Rorke M.A., Ellison M.V., Murray L.J. et al. Human papillomavirus related head and neck cancer survival: a systematic review and metaanalysis. Oral Oncol 2012;48(12):1191–201. DOI: 10.1016/j.oraloncology.2012.06.019.
11. Mahal B.A., Catalano P.J., Haddad R.I. et al. Incidence and demographic burden of HPVassociated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol Biomarkers Prev 2019;28(10):1660–7. DOI: 10.1158/10559965.EPI190038.
12. Chaturvedi A.K., Engels E.A., Pfeiffer R.M. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol 2011;29(32):4294–301. DOI: 10.1200/JCO.2011.36.4596.
13. Stjernstrøm K.D., Jensen J.S., Jakobsen K.K. et al. Current status of human papillomavirus positivity in oropharyngeal squamous cell carcinoma in Europe: a systematic review. Acta Otolaryngol 2019; 139(12):1112–6. DOI:10.1080/00016489.2019.1669820.
14. Mooren J.J., Gültekin S.E., Straetmans J.M. et al. P16 (INK4A) immunostaining is a strong indicator for highriskHPVassociated oropharyngeal carcinomas and dysplasias, but is unreliable to predict lowriskHPVinfection in head and neck papillomas and laryngeal dysplasias. Int J Cancer 2014;134(9):2108–17. DOI: 10.1002/ijc.28534.
15. Visalli G., Riso R., Facciolà A. et al. Higher levels of oxidative DNA damage in cervical cells are correlated with the grade of dysplasia and HPV infection. J Med Virol 2016;88(2):336–44. DOI: 10.1002/jmv.24327.
16. Prigge E.S., Arbyn M., von Knebel Doeberitz M., Reuschenbach M. Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and metaanalysis. Int J Cancer 2017;140(5): 1186–98. DOI: 10.1002/ijc.30516.
17. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129.
18. Human papillomavirus testing in head and neck carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline J Clin Oncol 2018;36(31):3152–61. DOI: 10.1200/JCO.18.00684.
19. Mudunov A.M. Virus papillomy cheloveka – novyĭ etiologicheskiĭ faktor v razvitii raka organov golovy i shei. Problemy i perspektivy ikh resheniya. Epidemiologiya i vaktsinoprofilaktika 2018; 17(5):100–5. DOI: 10.31631/207330462018175100105.
